Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Discovery
Sponsor : Spark Therapeutics, Inc
Deal Size : $216.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Spark secures exclusive worldwide rights to SpliceBio's proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy targeting an undisclosed inherited retinal disease.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 17, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery
Sponsor : Spark Therapeutics, Inc
Deal Size : $216.0 million
Deal Type : Licensing Agreement
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Ysios Capital
Deal Size : $56.6 million
Deal Type : Series A Financing
Details : The proceeds from the financing, the largest Series A round for a Spanish biotech company, will enable SpliceBio to build a pipeline of Protein Splicing gene therapy programs, while advancing the lead program in Stargardt disease to the clinic.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 16, 2022
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Ysios Capital
Deal Size : $56.6 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?
Reset All
